Myocardial hypertrophy overrides the angiogenic response to hypoxia

PLoS ONE

Volumn 3, Issue 12, 2008, Pages

  Choi, Yeong Hoon ^a,b   Cowan, Douglas B ^a   Nathan, Meena ^a   Poutias, Dimitrios ^a   Stamm, Christof ^a   del Nido, Pedro J ^a   McGowan Jr , Francis X ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PIMONIDAZOLE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN CONTAINING PROTEIN 1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; TRANSCRIPTION FACTOR; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL TISSUE; ARTERIAL OXYGEN SATURATION; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; CYANOSIS; HEART VENTRICLE HYPERTROPHY; HEMATOCRIT; HYPOXIA; IMMUNOHISTOCHEMISTRY; NEWBORN; NONHUMAN; OXYGEN CONCENTRATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RABBIT; SHAM PROCEDURE; SIGNAL TRANSDUCTION; ANIMAL; ANOXIA; BIOLOGICAL MODEL; CAPILLARY; GENE EXPRESSION REGULATION; HEART MUSCLE; HYPERTROPHY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ORYCTOLAGUS CUNICULUS;

ANIMALS; ANIMALS, NEWBORN; ANOXIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CAPILLARIES; GENE EXPRESSION REGULATION; HYPERTROPHY; MODELS, BIOLOGICAL; MYOCARDIUM; NEOVASCULARIZATION, PATHOLOGIC; RABBITS; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 58149178556     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004042     Document Type: Article

References (41)

1. Allard MF, Flint JD, English JC, Henning SL, Salamanca MC, et al. (1994) Calcium overload during reperfusion is accelerated in isolated hypertrophied rat hearts. J Mol Cell Cardiol 26: 1551-1563.
2. Sink JD, Pellom GL, Currie WD, Hill RC, Olsen CO, et al. (1981) Response of hypertrophied myocardium to ischemia: correlation with biochemical and physiological parameters. J Thorac Cardiovasc Surg 81: 865-872.
3. Friehs I, del Nido PJ (2003) Increased susceptibility of hypertrophied hearts to ischemic injury. Ann Thorac Surg 75: S678-684.
4. Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Activation of the HIF pathway in cancer. Curr Opin Genet Dev 11: 293-299.
5. Friehs I, Moran AM, Stamm C, Colan SD, Takeuchi K, et al. (1999) Impaired glucose transporter activity in pressure-overload hypertrophy is an early indicator of progression to failure. Circulation 100: II187-193.
6. Takeuchi K, McGowan FX Jr, Glynn P, Moran AM, Rader CM, et al. (1998) Glucose transporter upregulation improves ischemic tolerance in hypertrophied failing heart. Circulation 98: II234-239; discussion II240-231.
7. Baker EJ, Boerboom LE, Olinger GN, Baker JE (1995) Tolerance of the developing heart to ischemia: impact of hypoxemia from birth. Am J Physiol 268: H1165-1173.
8. Baker JE, Contney SJ, Gross GJ, Bosnjak ZJ (1997) KATP channel activation in a rabbit model of chronic myocardial hypoxia. J Mol Cell Cardiol 29: 845-848.
9. Baker JE, Curry BD, Olinger GN, Gross GJ (1997) Increased tolerance of the chronically hypoxic immature heart to ischemia. Contribution of the KATP channel. Circulation 95: 1278-1285.
10. Del Nido PJ, Glynn P, Buenaventura P, Salama G, Koretsky AP (1998) Fluorescence measurement of calcium transients in perfused rabbit heart using rhod 2. Am J Physiol 274: H728-741.
11. Stamm C, Friehs I, Cowan DB, Cao-Danh H, Choi YH, et al. (2002) Dopamine treatment of postischemic contractile dysfunction rapidly induces calcium-dependent pro-apoptotic signaling. Circulation 106: I290-298.
12. Andrews NC, Faller DV (1991) A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19: 2499.
13. Cowan DB, Poutias DN, Del Nido PJ, McGowan FX Jr (2000) CD14-independent activation of cardiomyocyte signal transduction by bacterial endotoxin. Am J Physiol Heart Circ Physiol 279: H619-629.
14. Cowan DB, Weisel RD, Williams WG, Mickle DA (1993) Identification of oxygen responsive elements in the 5′-flanking region of the human glutathione peroxidase gene. J Biol Chem 268: 26904-26910.
15. Rivard A, Berthou-Soulie L, Principe N, Kearney M, Curry C, et al. (2000) Age-dependent defect in vascular endothelial growth factor expression is associated with reduced hypoxia-inducible factor 1 activity. J Biol Chem 275: 29643-29647.
16. Friehs I, Moran AM, Stamm C, Choi YH, Cowan DB, et al. (2004) Promoting angiogenesis protects severely hypertrophied hearts from ischemic injury. Ann Thorac Surg 77: 2004-2010; discussion 2011.
17. Arteel GE, Thurman RG, Raleigh JA (1998) Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem 253: 743-750.
18. Semenza GL, Wang GL (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454.
19. Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, et al. (2003) Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 278: 11032-11040.
20. Kim CH, Cho YS, Chun YS, Park JW, Kim MS (2002) Early expression of myocardial HIF-1alpha in response to mechanical stresses: regulation by stretch-activated channels and the phosphatidylinositol 3-kinase signaling pathway. Circ Res 90: E25-33.
21. Carroll VA, Ashcroft M (2006) Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66: 6264-6270.
22. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, et al. (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25: 5675-5686.
23. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC (2003) Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23: 9361-9374.
24. Uchida T, Rossignol F, Matthay MA, Mounier R, Couette S, et al. (2004) Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha. J Biol Chem 279: 14871-14878.
25. Shohet RV, Garcia JA (2007) Keeping the engine primed: HIF factors as key regulators of cardiac metabolism and angiogenesis during ischemia. J Mol Med 85: 1309-1315.
26. Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, et al. (2006) Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10: 413-423.
27. Lisy K, Peet DJ (2008) Turn me on: regulating HIF transcriptional activity. Cell Death Differ 15: 642-649.
28. Aprelikova O, Wood M, Tackett S, Chandramouli GV, Barrett JC (2006) Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection. Cancer Res 66: 5641-5647.
29. Elvert G, Kappel A, Heidenreich R, Englmeier U, Lanz S, et al. (2003) Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha ) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J Biol Chem 278: 7520-7530.
30. Dutta D, Ray S, Vivian JL, Paul S (2008) Activation of the VEGFR1 chromatin domain: an angiogenic signal-ETS1/HIF-2alpha regulatory axis. J Biol Chem 283: 25404-25413.
31. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, et al. (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991.
32. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269: 26988-26995.
33. Kendall RL, Thomas KA (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 90: 10705-10709.
34. Kendall RL, Wang G, Thomas KA (1996) Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226: 324-328.
35. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, et al. (1995) A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 10: 135-147.
36. Park JE, Chen HH, Winer J, Houck KA, Ferrara N (1994) Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 269: 25646-25654.
37. Roskoski R Jr (2008) VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem Biophys Res Commun 375: 287-291.
38. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M (1998) Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A 95: 9349-9354.
39. Petrova TV, Makinen T, Alitalo K (1999) Signaling via vascular endothelial growth factor receptors. Exp Cell Res 253: 117-130.
40. Ahmad S, Ahmed A (2004) Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 95: 884-891.
41. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, et al. (2007) p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446: 444-448.